NATCO Pharma launches generic semaglutide injection in India on the day of patent expiry, introducing multi-dose vials priced from ₹1,290 per month to improve access to GLP-1 therapy for type 2 diabetes.
Written By: Karthik Teja Macharla, PharmD
Reviewed By: Pharmacally Editorial Team
NATCO Pharma Limited has announced the launch of generic semaglutide injection in India, marking its market entry on the very day the patent for the GLP-1 therapy expires. The company will introduce the product in multi-dose vial format under the brand names Semanat and Semafull, positioning it as a significantly lower-cost alternative for patients with type 2 diabetes.
The launch follows approval from the Central Drugs Standard Control Organisation (CDSCO) in February 2026 to manufacture and market semaglutide in both multi-dose vials and pen-device formats. The approval was supported by a clinical comparison study. Semaglutide is indicated as an adjunct to diet and exercise for adults with insufficiently controlled type 2 diabetes mellitus.
NATCO’s initial rollout will focus on multi-dose vial presentations in strengths of 2 mg/1.5 mL, 4 mg/3 mL, and 8 mg/3 mL. The company has set the monthly maximum retail price at ₹1,290 for the 2 mg/1.5 mL and 4 mg/3 mL doses, while the 8 mg/3 mL strength will be priced at ₹1,750 per month.
A pen-device version is also planned, with launch expected in April 2026. The monthly MRP for the pen format will be ₹4,000, ₹4,200, and ₹4,500 for the 2 mg/1.5 mL, 4 mg/3 mL, and 8 mg/3 mL strengths, respectively.
According to the company, NATCO is the first manufacturer to introduce generic semaglutide in multi-dose vial form in India, accompanied by customized syringes for administration. The company also intends to make the product available to third-party partners for co-marketing.
NATCO noted that the vial format significantly reduces treatment cost, making it around 70% cheaper than pen-device formulations and nearly 90% lower than the innovator brand’s price. The company believes the pricing strategy could improve patient access to GLP-1 therapy and support long-term adherence among individuals managing type 2 diabetes.
Reference
NATCO Pharma Launches Semaglutide Generic Injection Multi Dose Vials in India at the Most Affordable Price Starting from MRP INR 1,290, 20 March 2026, https://www.natcopharma.co.in/insights/news-and-announcements
About the Writer
Karthik Teja Macharla, PharmD is a Pharm.D. graduate with a strong interest in clinical research, pharmacovigilance, and medical writing. In his words, he is passionate about converting complex medical information into clear, evidence-based scientific communication, committed to contributing to patient safety and advancing healthcare through accurate and impactful medical content.